Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NRAS Q61K |
| Therapy | Ganitumab + Trametinib |
| Indication/Tumor Type | neuroblastoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS Q61K | neuroblastoma | sensitive | Ganitumab + Trametinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with the combination of Ganitumab (AMG-479) and Mekinist (trametinib) synergistically inhibited viability of two neuroblastoma cell lines harboring NRAS Q61K culture, and delayed tumor growth and enhanced survival in a cell line xenograft model (PMID: 39001383). | 39001383 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39001383) | Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma. | Full reference... |